Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832443 | 0.92 | CYP2C8 (0.76) | CYP2C8KMT2AMEN1RCE1KDM4E | |
| SCHEMBL832172 | 0.85 | CYP2C8 (0.76) | CYP2C8KMT2AMEN1RCE1KDM4E | |
| SCHEMBL12665818 | 0.84 | CYP2C8 (0.88) | CYP2C8KMT2AMEN1RCE1KDM4E | |
| SCHEMBL12665480 | 0.84 | CYP2C8 (1.00) | CYP2C8KMT2AMEN1RCE1KDM4E | |
| SCHEMBL12673768 | 0.84 | CYP2C8 (0.77) | CYP2C8KMT2AMEN1RCE1KDM4E | |
| SCHEMBL12665473 | 0.84 | CYP2C8 (0.84) | CYP2C8KMT2AMEN1RCE1KDM4E | |
| SCHEMBL12665636 | 0.84 | CYP2C8 (0.78) | CYP2C8KMT2AMEN1RCE1ALDH1A1 | |
| SCHEMBL832518 | 0.82 | CYP2C8 (0.79) | CYP2C8KMT2AMEN1RCE1FAAH | |
| SCHEMBL831646 | 0.81 | CYP2C8 (0.74) | CYP2C8KMT2AMEN1RCE1KDM4E | |
| SCHEMBL832521 | 0.79 | CYP2C8 (0.57) | CYP2C8KMT2AMEN1RCE1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197842-B1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORP (US) | 2012-05-23 | — | — | EP | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| WO-2009032116-A1 | 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | CYP2C8 847/4885KMT2A 321/4885MEN1 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.